Unlocking the Full Potential of Antibody-Based Conjugates through AJICAP® Site-Specific Conjugation and Linker Technologies

• AJICAP® Conjugation: Leveraging Site-Specific Technologies in Next-Generation ADCs to Enhance Clinically Relevant Biological Properties through Precise DAR Control.
• AJICAP® Linker: Demonstrating a Novel Hydrophilic Linker Technology that Enhances Stability and Enables Versatile Synthesis of ADCs with Higher DAR.
• AJICAP-derived ADCs Exhibiting High In-Vivo Stability in NHP Studies, Supporting their Suitability for Further Development.
• Beyond Conventional ADCs: Site-Specific Conjugation of Bispecific Antibodies and Antibody–Oligonucleotide Conjugates

Speakers:

Tsubasa Aoki

Research Scientist

Ajinomoto Co., Inc.